DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
P••••••• L••
Pharmaceuticalsgroup grade Aon a schedule nowsponsor unattributed
What matters now
- 94¢ → 95¢consensus mark
Consensus mark 95¢ on cost, up from 94¢ a year ago, 93¢ last quarter.
Q2 2026 · The lenders' own valuations moved back up.
Derived1 of 1 lender' own marks, weighted by principal - $8.89Mprincipal outstanding
$8.89M principal held by 1 lender; matures Jul 2028.
Q2 2026 · Refinancing is due in 21 months at a 95¢ mark.
FactBDC schedules of investments, 30 Jun 2026; a sum of the BDCs' pieces, a lower bound
Mark path, consensus per quarter end
94¢ · 91¢ · 95¢ · 93¢ · 95¢Q2 2025 to Q2 2026
Principal held
at least $8.9M
sum of BDC pieces, a lower bound
Fair value
$8.4M
95c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
4
1 on the latest quarter
Facilities
2
0 equity pieces beside them
Next maturity
Jul 6, 2028
no dated debt inside 24 months
On the tape since
Dec 31, 2021
latest Jun 30, 2026
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| P••••• S••••• C•••••• B•• I••• | $8.89M | 95¢ | +2 pts |
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| P••••• S••••• C•••••• B•• I••• | term loan first lien Investment F•••• L••• S••••• S•••••• L••• I••••••• R••• 8.69% (S +CSA + 4.75%) M••••••• D• | $8.9M | $8.4M 95c | SOFR+475 bp |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $8.9M | 95c | SOFR+475 bp | Jul 6, 2028 | 2 |
| other lien unstated exited Dec 31, 2025 | at least $5.4M | 95c | S+475 bp | Jul 6, 2028 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $8.9M | $8.4M | 95c | 0 |
| Mar 31, 2026 | 1 | $9.0M | $8.3M | 93c | 0 |
| Dec 31, 2025 | 2 | $23.3M | $22.1M | 95c | 0 |
| Sep 30, 2025 | 3 | $20.2M | $18.0M | 91c | 0 |
All 17 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 2 | $15.4M | $14.5M | 94c | 0 |
| Mar 31, 2025 | 2 | $28.6M | $26.9M | 94c | 0 |
| Dec 31, 2024 | 2 | $62.7M | $58.3M | 93c | 0 |
| Sep 30, 2024 | 2 | $36.9M | $34.5M | 94c | 0 |
| Jun 30, 2024 | 1 | $29.4M | $28.8M | 98c | 0 |
| Mar 31, 2024 | 1 | $29.4M | $28.2M | 96c | 0 |
| Dec 31, 2023 | 2 | $36.0M | $34.8M | 97c | 0 |
| Sep 30, 2023 | 1 | $29.4M | $28.6M | 98c | 0 |
| Jun 30, 2023 | 1 | $29.4M | $27.9M | 95c | 0 |
| Mar 31, 2023 | 1 | $29.4M | $26.9M | 92c | 0 |
| Dec 31, 2022 | 1 | $29.4M | $26.2M | 89c | 0 |
| Sep 30, 2022 | 1 | $29.4M | $25.7M | 88c | 0 |
| Dec 31, 2021 | 1 | $10.4M | $10.3M | 100c | 0 |
What changed
- Facility left every BDC scheduleDec 31, 2025
- Lender left a facilitySep 30, 2025
- New lender joined a facilitySep 30, 2025
- Marked down (one lender)Sep 30, 2022
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- PADAGISderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 4 BDCsderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it